Ryuichi Iwakiri

Ryuichi Iwakiri

Auto-generated profile, based on publicly available information

Ryuichi Iwakiri

Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2006 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
YEYuichiro Eguchi
Yuichiro Eguchi
TETakahisa Eguchi
Takahisa Eguchi
TMToshihiko Mizuta
Toshihiko Mizuta
YIYasushi Ide
Yasushi Ide
TYTsutomu Yasutake
Tsutomu Yasutake
NONaofumi Ono
Naofumi Ono

4 December 2018 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
HHHidenori Hidaka
Hidenori Hidaka
KHKen Higashimoto
Ken Higashimoto
SASaori Aoki
Saori Aoki
HMHiroyuki Mishima
Hiroyuki Mishima
CHChisa Hayashida
Chisa Hayashida
SHSoejima Hidenobu
Soejima Hidenobu
Imprinted genes are regulated by DNA methylation at imprinting-associated differentially methylated regions (iDMRs). Abnormal expression of imprinted genes is implicated in imprinting disorders and tumors. In colorectal cancer (CRC), methylation and imprinting status of the IGF2/H19 domain have been studied. However, no comprehensive methylation analysis of iDMRs in CRC has been reported. Furthermore, the relationship between iDMR methylation status and other methylation-related issues, such as CpG island methylator phenotype (CIMP) and long interspersed element-1 (LINE-1) methylation, remains unclear. We analyzed the methylation status of 38 iDMRs in 106 CRC patients. We also investigated CIMP, LINE-1 methylation, KRAS and BRAF gene mutations, and loss of imprinting (LOI) of IGF2. We further examined the relationship between these factors and clinicopathological factors. The overall trend in iDMR methylation was towards hypermethylation, and iDMRs could be grouped into three categories: susceptible, resistant, and intermediate-to-aberrant methylation. The susceptible and resistant iDMRs consisted of all types of iDMR (gametic and somatic, maternally and paternally methylated). Hypermethylation of multiple iDMRs (HyMiD)-positive status was statistically associated with CIMP-positive status, but not associated with mutations in the BRAF and KRAS genes. HyMiD-positive status was inversely associated with LINE-1 methylation. Among four iDMRs within the IGF2/H19 domain, IGF2-DMR0 hypomethylation occurred most frequently, but was not associated with IGF2 LOI. Finally, we statistically calculated predictive prognostic scores based on aberrant methylation status of three iDMRs. In CRC tissues, some iDMRs were susceptible to hypermethylation independent of the type of iDMR and genomic sequence. Although HyMiD-positive status was associated with CIMP-positive status, this was independent of the BRAF and KRAS pathways, which are responsible for CIMP. Since IGF2-DMR0 hypomethylation and aberrant methylation of other iDMRs within the IGF2/H19 domain were not associated with IGF2 LOI, dysfunction of any of the molecular components related to imprinting regulation may be involved in IGF2 LOI. The prognostic score calculated based on aberrant methylation of three iDMRs has potential clinical applications as a prognostic predictor in patients. Further study is required to understand the biological significance of, and mechanisms behind, aberrant methylation of iDMRs and IGF2 LOI in CRCs.

27 March 2021 in Digestive Endoscopy
Verified
Journal Article
Closed access
PDF file
YSYutaka Saito
Yutaka Saito
SKShinya Kodashima
Shinya Kodashima
TMTakahisa Matsuda
Takahisa Matsuda
KMKoji Matsuda
Koji Matsuda
MFMitsuhiro Fujishiro
Mitsuhiro Fujishiro
HIHaruhiro Inoue
Haruhiro Inoue

1 October 2005 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
KOKayoko Oda
Kayoko Oda
RIRyuichi Iwakiri
Ryuichi Iwakiri
MHMegumi Hara
Megumi Hara
KWKazuyo Watanabe
Kazuyo Watanabe
ADAkiko Danjo
Akiko Danjo
KFKazuma Fujimoto
Kazuma Fujimoto

26 June 2019 in Digestive Endoscopy
Verified
Journal Article
Closed access
PDF file
RIRyuichi Iwakiri
Ryuichi Iwakiri
KTKiyohito Tanaka
Kiyohito Tanaka
TGTakuji Gotoda
Takuji Gotoda
SOShiro Oka
Shiro Oka
TOTakao Ohtsuka
Takao Ohtsuka
HTHisao Tajiri
Hisao Tajiri

30 January 2021 in Intestinal Research
Verified
Journal Article
Open access
PDF file
THToshifumi Hibi
Toshifumi Hibi
IKIsao Kamae
Isao Kamae
Philippe PintonPhilippe Pinton
Philippe Pinton
LULyann Ursos
Lyann Ursos
RIRyuichi Iwakiri
Ryuichi Iwakiri
HPHaridarshan Patel
Haridarshan Patel
Background/Aims: Several biologic therapies are approved in Japan to treat moderately to severely active ulcerative colitis (UC), but there are no published comparative efficacy studies in a Japanese population. We compared the efficacy of biologics approved in Japan (adalimumab, infliximab, golimumab, and vedolizumab) for treating biologic-naïve patients with UC at their approved doses.Methods: A targeted literature review identified 4 randomized controlled trials of biologics for UC in biologicnaïve Japanese patients. For each study, efficacy outcome data from induction (weeks 6–12) and maintenance (weeks 30–60) treatment were extracted for analysis. Treatment effects on clinical response, clinical remission, and mucosal healing relative to the average placebo results across all trials were estimated using network meta-analyses followed by transformation into probabilities and odds ratios (OR).Results: At the end of induction, the likelihood of clinical response and clinical remission was highest with infliximab (OR: 2.12 and 2.35, respectively) and vedolizumab (OR: 2.10 and 2.32, respectively); the likelihood of mucosal healing was highest with infliximab (OR: 2.24) and adalimumab (OR: 1.86). During maintenance, the likelihood of clinical response and clinical remission was highest with vedolizumab (OR: 6.44 and 4.68, respectively) and golimumab (OR: 5.13 and 3.84, respectively); the likelihood of mucosal healing was significantly higher than placebo with all biologics.Conclusions: All active treatments were efficacious compared with placebo. Infliximab and vedolizumab had the highest odds for induction of clinical response, remission, and mucosal healing. Golimumab and vedolizumab had numerically higher odds of achieving efficacy outcomes in the maintenance phase.